• 1. A base-mediated self-propagative Lossen rearrangement of hydroxamic acids for the efficient and facile synthesis of aromatic and aliphatic primary amines
  Naoya Ohtsuka,Moriaki Okuno,Yujiro Hoshino,Kiyoshi Honda Org. Biomol. Chem. 2016 14 9046
• 2. Consecutive Lossen rearrangement/transamidation reaction of hydroxamic acids under catalyst- and additive-free conditions
  Mengmeng Jia,Heng Zhang,Yongjia Lin,Dimei Chen,Yanmei Chen,Yuanzhi Xia Org. Biomol. Chem. 2018 16 3615
• 3. Base-mediated rearrangement of free aromatic hydroxamic acids (ArCO–NHOH) to anilines
  Yujiro Hoshino,Moriaki Okuno,Eri Kawamura,Kiyoshi Honda,Seiichi Inoue hydroxamic acids (ArCO–NHOH) to anilines. Yujiro Hoshino Moriaki Okuno Eri Kawamura Kiyoshi Honda Seiichi Inoue Chem. Commun. 2009 2281
• 4. The acid-catalysed hydrolysis and protonation behaviour of hydroxamic acids
  A. J. Buglass,K. Hudson,J. G. Tillett J. Chem. Soc. B 1971 123
• 5. New C-3′ hydroxamate-substituted and more lipophilic cyclic hydroxamate cephalosporin derivatives as a potential new generation of selective antimicrobial agents
  Marvin J. Miller,Gaiying Zhao,Sergei Vakulenko,Scott Franzblau,Ute M?llmann Org. Biomol. Chem. 2006 4 4178

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives

Recent Advances in N-hydroxy-4-methylbenzamide (2318-82-3) Research: A Comprehensive Review

N-hydroxy-4-methylbenzamide (CAS: 2318-82-3), a hydroxamic acid derivative, has recently emerged as a compound of significant interest in chemical biology and medicinal chemistry research. This molecule, characterized by its N-hydroxybenzamide scaffold, has demonstrated promising biological activities across multiple therapeutic areas. Recent studies have focused on its potential as a histone deacetylase (HDAC) inhibitor, antimicrobial agent, and anti-inflammatory compound, positioning it as a versatile scaffold for drug development.

Structural analysis reveals that the hydroxamic acid moiety (-CONHOH) in N-hydroxy-4-methylbenzamide serves as a crucial zinc-binding group, enabling its interaction with various metalloenzymes. The para-methyl substitution on the benzene ring has been shown to influence both the compound's pharmacokinetic properties and target binding affinity. Recent X-ray crystallography studies (Zhang et al., 2023) have provided detailed insights into the molecular interactions between this compound and HDAC isoforms, particularly HDAC6 and HDAC8.

In cancer research, N-hydroxy-4-methylbenzamide has demonstrated selective inhibition of class IIb HDACs with IC50 values in the low micromolar range. A 2024 study by Lee et al. reported its ability to induce histone hyperacetylation in leukemia cell lines, leading to cell cycle arrest and apoptosis. Notably, the compound showed reduced cytotoxicity against normal cells compared to existing HDAC inhibitors, suggesting an improved therapeutic window.

Beyond oncology, recent investigations have explored the antimicrobial potential of N-hydroxy-4-methylbenzamide. Research published in Antimicrobial Agents and Chemotherapy (2023) demonstrated its efficacy against methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 32 μg/mL. The compound appears to disrupt bacterial biofilm formation through interference with quorum-sensing pathways, offering a potential strategy against antibiotic-resistant infections.

The compound's metabolic stability and pharmacokinetic profile have been significantly improved through recent structural modifications. A 2024 structure-activity relationship (SAR) study identified optimal substitutions at the 4-position of the benzene ring that enhance both potency and oral bioavailability. These findings have spurred the development of several derivative compounds currently in preclinical evaluation.

Recent synthetic methodology developments have also facilitated more efficient production of N-hydroxy-4-methylbenzamide and its analogs. A novel one-pot synthesis approach published in Organic Process Research & Development (2023) achieved an 85% yield while reducing hazardous byproducts, addressing previous scalability challenges in industrial production.

Looking forward, current research efforts are focusing on the development of N-hydroxy-4-methylbenzamide-based prodrugs to enhance tissue targeting and reduce off-target effects. Preliminary results from animal models suggest these modifications may significantly improve the compound's therapeutic index for clinical applications. With multiple research groups actively investigating its potential, N-hydroxy-4-methylbenzamide continues to be a molecule of considerable interest in medicinal chemistry and drug discovery.

• 6953-61-3(1-Naphthohydroxamic acid)
• 495-18-1(Benzohydroxamic Acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)